A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma
The purpose of this study is to find out the safety and effectiveness of 1064 Q-Switch Laser Therapy compared to Glycolic Acid Chemical Peels for the treatment of melasma.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
|Official Title:||A Pilot Study Comparing the Efficacy of 1064 Q-switch Laser vs. Glycolic Acid Peels for the Treatment of Melasma: A Randomized Control Trial|
- Change in best overall cosmetic appearance (right side or left side better)rated by a blinded dermatologist from baseline to week 10 [ Time Frame: 1 hour at baseline and week 10 ] [ Designated as safety issue: No ]The primary outcome was a blinded rating of the treatment area (1064nm Q-switch Laser Versus Glycolic Acid Peels) with the best overall cosmetic appearance. A dermatologist will blindly evaluate the treated areas of each side from live subjects at baseline and on the final follow up visit (week 10).
|Study Start Date:||October 2013|
|Estimated Study Completion Date:||October 2014|
|Estimated Primary Completion Date:||October 2014 (Final data collection date for primary outcome measure)|
Active Comparator: 1064nm Q-switch Laser
The 1064 Q-Switch Laser is a medical device that uses a focused laser to remove dark pigment (color) from the skin.
|Device: 1064nm Q-switch Laser|
Active Comparator: Glycolic Acid Peels
A Glycolic Acid Chemical Peel is a mild skin treatment used to correct uneven texture and color by removing dead cells from the skin's outermost layer.
|Other: Glycolic Acid Peels|
Participants in this study will be patients at the dermatology clinic who are clinically diagnosed with at least a 2X2 cm patch of melasma on each side of their face (forehead or cheek). Starting at 2 weeks before treatment (week 2), both sides will be pretreated and primed with 4% hydroquinone with, if necessary, 2.5% hydrocortisone cream BID. On the treatment day (2-weeks) and 6-weeks one half of the subject's face will receive glycolic acid peels and the other half of the face will receive 1064nm Q-switch laser. This study is a pilot study designed to determine feasibility of these procedures.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01976273
|Contact: Emily Poon, PhDfirstname.lastname@example.org|
|United States, Illinois|
|Northwestern University Department of Dermatology||Recruiting|
|Chicago, Illinois, United States, 60611|
|Contact: Emily Poon, PhD 312-695-4761 email@example.com|
|Principal Investigator: Murad Alam, MD|
|Principal Investigator:||Murad Alam, MD||Northwestern University|